- Home
- OTLK vs BRNS Comparison
OTLK vs BRNS Comparison
Compare OTLK & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- BRNS
- Stock Information
- Founded
- OTLK 2010
- BRNS 2016
- Country
- OTLK United States
- BRNS United Kingdom
- Employees
- OTLK N/A
- BRNS N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- BRNS Health Care
- Exchange
- OTLK Nasdaq
- BRNS Nasdaq
- Market Cap
- OTLK 48.3M
- BRNS 38.7M
- IPO Year
- OTLK 2016
- BRNS 2021
- Fundamental
- Price
- OTLK $1.77
- BRNS $1.07
- Analyst Decision
- OTLK Strong Buy
- BRNS Strong Buy
- Analyst Count
- OTLK 5
- BRNS 2
- Target Price
- OTLK $10.20
- BRNS $3.00
- AVG Volume (30 Days)
- OTLK 689.4K
- BRNS 51.1K
- Earning Date
- OTLK 05-15-2025
- BRNS 05-07-2025
- Dividend Yield
- OTLK N/A
- BRNS N/A
- EPS Growth
- OTLK N/A
- BRNS N/A
- EPS
- OTLK 0.83
- BRNS N/A
- Revenue
- OTLK N/A
- BRNS $14,969,000.00
- Revenue This Year
- OTLK N/A
- BRNS N/A
- Revenue Next Year
- OTLK $288.46
- BRNS N/A
- P/E Ratio
- OTLK $2.12
- BRNS N/A
- Revenue Growth
- OTLK N/A
- BRNS 4381.74
- 52 Week Low
- OTLK $0.87
- BRNS $0.64
- 52 Week High
- OTLK $9.25
- BRNS $2.14
- Technical
- Relative Strength Index (RSI)
- OTLK 57.64
- BRNS 59.44
- Support Level
- OTLK $1.55
- BRNS $0.65
- Resistance Level
- OTLK $1.90
- BRNS $1.11
- Average True Range (ATR)
- OTLK 0.18
- BRNS 0.12
- MACD
- OTLK 0.01
- BRNS 0.02
- Stochastic Oscillator
- OTLK 53.10
- BRNS 91.23
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.